Immunohistochemical analysis of tumours taken at humane endpoints or the end of the 6-week study revealed a 65% reduction in H460 tumour cell proliferation in mice treated with HM30-tesirine, with 28 ± 9.4% of cells staining positive for Ki67, compared to 83 ± 8.4% in control tumours (n = 3 individual tumours; p = 0.0016; Fig. 7g, h). This evidence concerns the gene MKI67 and neoplasm.